Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988;35(4):427-30.
doi: 10.1007/BF00561377.

Pharmacokinetics of ranitidine in patients undergoing haemofiltration

Affiliations

Pharmacokinetics of ranitidine in patients undergoing haemofiltration

U Gladziwa et al. Eur J Clin Pharmacol. 1988.

Abstract

The pharmacokinetics of ranitidine was investigated in 11 patients with acute or end stage renal failure during haemofiltration. Each patient received 50 mg ranitidine i.v. The mean distribution and elimination half lives were 0.13 and 2.57 h, respectively. The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively. About 17.1% of the administered dose was removed by haemofiltration (in approximately 20 l filtrate). Five of the patients still had some urine output and they excreted 0.1 to 11.8% of the dose in urine in 24 h. The haemofiltration clearance was 66.9 ml.min-1 at a filtrate flow rate of 86 ml.min-1, corresponding to a mean sieving coefficient of 0.78 (n = 6). As plasma concentrations were still in an effective range after haemofiltration, dose supplementation is not recommended.

PubMed Disclaimer

References

    1. Eur J Clin Pharmacol. 1987;32(6):587-91 - PubMed
    1. Br J Clin Pharmacol. 1986 Dec;22(6):749-50 - PubMed
    1. Clin Pharmacol Ther. 1982 Jun;31(6):770-4 - PubMed
    1. Gastroenterology. 1980 Dec;79(6):1267-71 - PubMed
    1. Postgrad Med J. 1983 Jan;59(687):25-7 - PubMed

LinkOut - more resources